Viola Zhu

6PUBLICATIONS
72CO-AUTHORS
Molecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul

|Dec 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.

Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul

|Apr 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell

|Dec 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance.

Egbert F Smit, Christophe Dooms, Jo Raskin

|Jun 02, 2021
Clinicopathologic Features and Response to Therapy of <i>NRG1</i> Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Alexander Drilon, Michael Duruisseaux, Ji-Youn Han

|Feb 06, 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in <i>ALK</i>-Rearranged NSCLC: A Report of Two Cases.

Viola W Zhu, Misako Nagasaka, Takafumi Kubota

Pageof 1

Frequent Collaborators

3 joint publications

Alexander Drilon

3 joint publications

D Ross Camidge

2 joint publications

Misako Nagasaka

2 joint publications

Linh Nguyen-Phuong